{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T15:11:41Z","timestamp":1783350701288,"version":"3.54.6"},"reference-count":49,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T00:00:00Z","timestamp":1747785600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005088","name":"Beijing Municipal Health Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005088","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Depression Chinese Medicine and Western Medicine","award":["2023BJSZDYNJBXTGG-014"],"award-info":[{"award-number":["2023BJSZDYNJBXTGG-014"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The combination of antiparkinsonics and antipsychotic drugs (AP) can improve the motor and mental symptoms of Parkinson\u2019s disease (PD) and reduce the actual burden of chronic disease care. To explore the adverse drug events (ADEs) worthy of attention in this treatment management process, we conducted a real-world pharmacovigilance analysis based on the FDA Adverse Event Reporting System (FAERS) database.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The Standard pharmacotherapy for PD includes Levodopa\/Carbidopa, Entacapone, Rasagiline, Pramipexole, Ropinirole, Rotigotine, Apomorphine, Amantadine, etc. Antipsychotic drug includes Quetiapine, Clozapine, and Pimavanserin. We collected the ADEs reports of FAERS that conformed to the combination regimens of anti-Parkinson\u2019s drugs and AP during the 20-year period from the third quarter of 2004 to the second quarter of 2024. Disproportionate analysis and subgroup analysis were conducted through 5 algorithms, namely \u03a9 shrinkage measure, additive model, multiplicative model, Combination risk ratio, and Chi-square. The time-to-onset (TTO) analysis was used to predict the variation of the risk size of ADEs occurrence over time. Finally, we explored the correlation between population characteristics and the occurrence of ADEs through Logistic regression.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We collected a total of 6297 cases, including 38\u2005316 ADEs records. The results of the disproportionate analysis show that the ADEs with the highest occurrence frequency include hallucination, general physical health deterioration, somnolence, stoma site discharge, urinary tract infection, memory impairment, etc. The TTO analysis results showed that the median TTO for all ADEs was 657.50 days, the median TTO for infection and inflammation was 716.00 days, and the median TTO for psychiatric symptoms was 823.00 days. All median TTOs conform to the early failure curve. The results of Logistic regression showed that gender was correlated with the occurrence of infection and inflammation, and the female population was more inclined to have important medical events related to infection and inflammation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>During the combined application of antiparkinsonics and AP, in addition to ADEs such as movement disorders and emerging mental symptoms, the risks of infection and inflammation should also be given key attention. Long-term follow-up should run through the entire process of disease diagnosis and treatment, and attention should be paid to the influence of drug dosage forms and dosages. The medication plan should be adjusted in a timely manner when ADEs occur.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ijnp\/pyaf033","type":"journal-article","created":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T01:09:09Z","timestamp":1747789749000},"source":"Crossref","is-referenced-by-count":8,"title":["Exploring the risk of adverse drug events in combination with antiparkinsonics and antipsychotics\u2014a two-decade real-world pharmacovigilance analysis based on the FAERS database"],"prefix":"10.1093","volume":"28","author":[{"given":"Junyi","family":"Wang","sequence":"first","affiliation":[{"name":"Beijing University of Chinese Medicine Second Clinical Medical School , Beijing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sen","family":"Lin","sequence":"additional","affiliation":[{"name":"The Fourth Clinical Medical College, Guangzhou University of Chinese Medicine , Guangzhou ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Bai","sequence":"additional","affiliation":[{"name":"Beijing University of Chinese Medicine Second Clinical Medical School , Beijing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huimin","family":"Zhang","sequence":"additional","affiliation":[{"name":"The First Clinical Medical College, Guangzhou University of Chinese Medicine , Guangzhou ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoqi","family":"Liu","sequence":"additional","affiliation":[{"name":"Beijing University of Chinese Medicine Second Clinical Medical School , Beijing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Wang","sequence":"additional","affiliation":[{"name":"Beijing University of Chinese Medicine Second Clinical Medical School , Beijing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5480-398X","authenticated-orcid":false,"given":"Rongjuan","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Neurology II, Beijing University of Chinese Medicine Dongfang Hospital , Beijing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,5,21]]},"reference":[{"key":"2025081905512991600_CIT0001","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/S1474-4422(17)30299-5","article-title":"Global, regional, and national burden of neurological disorders during 1990\u20132015: a systematic analysis for the Global Burden of Disease Study 2015","volume":"16","author":"Group G. 2015 NDC","year":"2017","journal-title":"Lancet Neurol."},{"key":"2025081905512991600_CIT0002","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.mcna.2018.10.014","article-title":"Parkinson\u2019s disease","volume":"103","author":"Reich","year":"2019","journal-title":"Med Clin North Am."},{"key":"2025081905512991600_CIT0003","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/S1474-4422(21)00030-2","article-title":"Challenges in the diagnosis of Parkinson\u2019s disease","volume":"20","author":"Tolosa","year":"2021","journal-title":"Lancet Neurol."},{"key":"2025081905512991600_CIT0004","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1093\/aje\/kwg068","article-title":"Incidence of Parkinson\u2019s disease: variation by age, gender, and race\/ethnicity","volume":"157","author":"Van Den Eeden","year":"2003","journal-title":"Am J Epidemiol."},{"key":"2025081905512991600_CIT0005","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.amjmed.2019.03.001","article-title":"Parkinson\u2019s disease and Parkinsonism","volume":"132","author":"Hayes","year":"2019","journal-title":"Am J Med."},{"key":"2025081905512991600_CIT0006","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","article-title":"Parkinson\u2019s disease","volume":"386","author":"Kalia","year":"2015","journal-title":"Lancet (London, England)."},{"key":"2025081905512991600_CIT0007","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/s00702-017-1686-y","article-title":"Epidemiology of Parkinson\u2019s disease","volume":"124","author":"Tysnes","year":"2017","journal-title":"J Neural Transm."},{"key":"2025081905512991600_CIT0008","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/S1474-4422(21)00061-2","article-title":"Progress towards therapies for disease modification in Parkinson\u2019s disease","volume":"20","author":"Vijiaratnam","year":"2021","journal-title":"Lancet Neurol."},{"key":"2025081905512991600_CIT0009","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nrneurol.2016.200","article-title":"The psychosis spectrum in Parkinson disease","volume":"13","author":"Ffytche","year":"2017","journal-title":"Nat Rev Neurol."},{"key":"2025081905512991600_CIT0010","doi-asserted-by":"publisher","first-page":"e068718","DOI":"10.1136\/bmj-2021-068718","article-title":"Management of psychiatric and cognitive complications in Parkinson\u2019s disease","volume":"379","author":"Weintraub","year":"2022","journal-title":"BMJ."},{"key":"2025081905512991600_CIT0011","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1097\/JGP.0b013e31821f1b41","article-title":"Prevalence of psychotic symptoms in a community-based Parkinson\u2019s disease sample","volume":"20","author":"Mack","year":"2012","journal-title":"Am J Geriatr Psychiatry."},{"key":"2025081905512991600_CIT0012","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1002\/mds.22839","article-title":"The changing face of Parkinson\u2019s disease-associated psychosis: a cross-sectional study based on the new NINDS-NIMH criteria","volume":"25","author":"F\u00e9nelon","year":"2010","journal-title":"Mov Disord."},{"key":"2025081905512991600_CIT0013","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.parkreldis.2019.10.018","article-title":"Increases in institutionalization, healthcare resource utilization, and mortality risk associated with Parkinson disease psychosis: retrospective cohort study","volume":"68","author":"Wetmore","year":"2019","journal-title":"Parkinsonism Relat Disord."},{"key":"2025081905512991600_CIT0014","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1002\/mds.27602","article-title":"Update on treatments for nonmotor symptoms of Parkinson\u2019s disease\u2014an evidence-based medicine review","volume":"34","author":"Seppi","year":"2019","journal-title":"Mov Disord."},{"key":"2025081905512991600_CIT0015","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1002\/mds.29700","article-title":"Management of impulse control and related disorders in Parkinson\u2019s disease: an expert consensus","volume":"39","author":"Debove","year":"2024","journal-title":"Mov Disord."},{"key":"2025081905512991600_CIT0016","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1002\/1531-8257(200003)15:2&lt;201::aid-mds1001&gt;3.0.co;2-d","article-title":"Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson\u2019s disease","volume":"15","author":"Friedman","year":"2000","journal-title":"Mov Disord."},{"key":"2025081905512991600_CIT0017","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.3390\/biomedicines12102317","article-title":"Treatment of Parkinson\u2019s disease psychosis-a systematic review and multi-methods approach","volume":"12","author":"Rose","year":"2024","journal-title":"Biomedicines."},{"key":"2025081905512991600_CIT0018","doi-asserted-by":"publisher","first-page":"e0278262","DOI":"10.1371\/journal.pone.0278262","article-title":"Assessing the risks of treatment in Parkinson disease psychosis: an in-depth analysis","volume":"18","author":"Longardner","year":"2023","journal-title":"PLoS One."},{"key":"2025081905512991600_CIT0019","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1212\/WNL.0000000000006396","article-title":"Mortality in patients with Parkinson disease psychosis receiving pimavanserin and quetiapine","volume":"91","author":"Moreno","year":"2018","journal-title":"Neurology."},{"key":"2025081905512991600_CIT0020","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1176\/appi.ajp.21090876","article-title":"Mortality among Parkinson\u2019s disease patients treated with pimavanserin or atypical antipsychotics: an observational study in medicare beneficiaries","volume":"179","author":"Mosholder","year":"2022","journal-title":"Am J Psychiatry."},{"key":"2025081905512991600_CIT0021","doi-asserted-by":"publisher","first-page":"80","DOI":"10.31083\/j.jin2304080","article-title":"Clearing the fog: a review of antipsychotics for Parkinson\u2019s-related hallucinations: a focus on pimavanserin, quetiapine and clozapine","volume":"23","author":"Abdul-Rahman","year":"2024","journal-title":"J Integr Neurosci."},{"key":"2025081905512991600_CIT0022","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1097\/JCP.0000000000001927","article-title":"Myocarditis on Clozapine 50\u00a0mg\/d in a patient with Parkinson\u2019s disease","volume":"44","author":"Skoble","year":"2024","journal-title":"J Clin Psychopharmacol."},{"key":"2025081905512991600_CIT0023","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1177\/08919887231154933","article-title":"Comparative efficacy, safety, and acceptability of pimavanserin and other atypical antipsychotics for Parkinson\u2019s disease psychosis: systematic review and network meta-analysis","volume":"36","author":"Yunusa","year":"2023","journal-title":"J Geriatr Psychiatry Neurol."},{"key":"2025081905512991600_CIT0024","doi-asserted-by":"publisher","first-page":"3057","DOI":"10.1002\/sim.3247","article-title":"A statistical methodology for drug-drug interaction surveillance","volume":"27","author":"Nor\u00e9n","year":"2008","journal-title":"Stat Med."},{"key":"2025081905512991600_CIT0025","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1111\/j.1365-2125.2007.02900.x","article-title":"Detecting signals of drug\u2013drug interactions in a spontaneous reports database","volume":"64","author":"Thakrar","year":"2007","journal-title":"Br J Clin Pharmacol."},{"key":"2025081905512991600_CIT0026","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1007\/s00228-017-2233-3","article-title":"Utilization of chi-square statistics for screening adverse drug-drug interactions in spontaneous reporting systems","volume":"73","author":"Gosho","year":"2017","journal-title":"Eur J Clin Pharmacol."},{"key":"2025081905512991600_CIT0027","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/s11095-020-02801-3","article-title":"Comparison of signal detection algorithms based on frequency statistical model for drug-drug interaction using spontaneous reporting systems","volume":"37","author":"Noguchi","year":"2020","journal-title":"Pharm Res."},{"key":"2025081905512991600_CIT0028","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s00401-010-0664-3","article-title":"Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders","volume":"119","author":"Beach","year":"2010","journal-title":"Acta Neuropathol (Berl)."},{"key":"2025081905512991600_CIT0029","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","article-title":"Staging of brain pathology related to sporadic Parkinson\u2019s disease","volume":"24","author":"Braak","year":"2003","journal-title":"Neurobiol Aging."},{"key":"2025081905512991600_CIT0030","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.nbd.2011.12.041","article-title":"Psychosis, apathy, depression and anxiety in Parkinson\u2019s disease","volume":"46","author":"Gallagher","year":"2012","journal-title":"Neurobiol Dis."},{"key":"2025081905512991600_CIT0031","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1097\/YCO.0b013e3283577ed1","article-title":"Psychiatric syndromes in Parkinson\u2019s disease","volume":"25","author":"Starkstein","year":"2012","journal-title":"Curr Opin Psychiatry."},{"key":"2025081905512991600_CIT0032","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1002\/mds.23829","article-title":"The movement disorder society evidence-based medicine review update: treatments for the motor symptoms of Parkinson\u2019s disease","volume":"26","author":"Fox","year":"2011","journal-title":"Mov Disord"},{"key":"2025081905512991600_CIT0033","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1002\/mds.27372","article-title":"International Parkinson and movement disorder society evidence-based medicine review: update on treatments for the motor symptoms of Parkinson\u2019s disease","volume":"33","author":"Fox","year":"2018","journal-title":"Mov Disord."},{"key":"2025081905512991600_CIT0034","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s00228-002-0441-x","article-title":"Antipsychotics and Parkinson\u2019s disease: association with disease and drug choice during the first 5 years of antiparkinsonian drug treatment","volume":"58","author":"van de Vijver D a","year":"2002","journal-title":"Eur J Clin Pharmacol."},{"key":"2025081905512991600_CIT0035","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1002\/mds.23719","article-title":"Incidence, prescription patterns, and determinants of antipsychotic use in patients with Parkinson\u2019s disease","volume":"26","author":"Wang","year":"2011","journal-title":"Mov Disord."},{"key":"2025081905512991600_CIT0036","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1007\/s40266-016-0416-8","article-title":"Psychosis in Parkinson disease: a review of etiology, phenomenology, and management","volume":"33","author":"Samudra","year":"2016","journal-title":"Drugs Aging."},{"key":"2025081905512991600_CIT0037","doi-asserted-by":"publisher","first-page":"262","DOI":"10.9740\/mhc.2017.11.262","article-title":"Treatment of psychotic symptoms in patients with Parkinson disease","volume":"7","author":"Chen","year":"2017","journal-title":"Ment Health Clin."},{"key":"2025081905512991600_CIT0038","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1007\/s40263-020-00765-x","article-title":"Effects of antipsychotic drugs: cross talk between the nervous and innate immune system","volume":"34","author":"Dinesh","year":"2020","journal-title":"CNS Drugs."},{"key":"2025081905512991600_CIT0039","doi-asserted-by":"publisher","first-page":"S93","DOI":"10.3233\/jpd-223228","article-title":"Age-related adaptive immune changes in Parkinson\u2019s disease","volume":"12","author":"Kouli","year":"2022","journal-title":"J Park Dis."},{"key":"2025081905512991600_CIT0040","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1007\/s00018-012-0970-0","article-title":"Immune aging and autoimmunity","volume":"69","author":"Goronzy","year":"2012","journal-title":"Cell Mol Life Sci."},{"key":"2025081905512991600_CIT0041","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1097\/YCO.0000000000000594","article-title":"Antipsychotics and the microbiota","volume":"33","author":"Chen","year":"2020","journal-title":"Curr Opin Psychiatry."},{"key":"2025081905512991600_CIT0042","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s40035-023-00392-8","article-title":"Parkinson\u2019s disease and gut microbiota: from clinical to mechanistic and therapeutic studies","volume":"12","author":"Zhang","year":"2023","journal-title":"Transl Neurodegener."},{"key":"2025081905512991600_CIT0043","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s12974-022-02510-1","article-title":"The function of gut microbiota in immune-related neurological disorders: a review","volume":"19","author":"Sittipo","year":"2022","journal-title":"J Neuroinflammation."},{"key":"2025081905512991600_CIT0044","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.autrev.2016.07.022","article-title":"Parkinson\u2019s disease: autoimmunity and neuroinflammation","volume":"15","author":"De Virgilio","year":"2016","journal-title":"Autoimmun Rev."},{"key":"2025081905512991600_CIT0045","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.jns.2012.07.026","article-title":"Gender differences in motor and non-motor symptoms among Sardinian patients with Parkinson\u2019s disease","volume":"323","author":"Solla","year":"2012","journal-title":"J Neurol Sci."},{"key":"2025081905512991600_CIT0046","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1212\/wnl.55.9.1358","article-title":"Parkinson\u2019s disease and parkinsonism in a longitudinal study: two-fold higher incidence in men. ILSA Working Group. Italian Longitudinal Study on Aging","volume":"55","author":"Baldereschi","year":"2000","journal-title":"Neurology."},{"key":"2025081905512991600_CIT0047","doi-asserted-by":"publisher","first-page":"501","DOI":"10.3233\/JPD-191683","article-title":"Parkinson\u2019s disease in women and men: what\u2019s the difference","volume":"9","author":"Cerri","year":"2019","journal-title":"J Park Dis."},{"key":"2025081905512991600_CIT0048","doi-asserted-by":"publisher","first-page":"e8856","DOI":"10.1371\/journal.pone.0008856","article-title":"Evidence for gender-specific transcriptional profiles of nigral dopamine neurons in Parkinson disease","volume":"5","author":"Simunovic","year":"2010","journal-title":"PLoS One."},{"key":"2025081905512991600_CIT0049","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1002\/cne.24574","article-title":"Postnatal developmental trajectory of dopamine receptor 1 and 2 expression in cortical and striatal brain regions","volume":"527","author":"Cullity","year":"2019","journal-title":"J Comp Neurol."}],"container-title":["International Journal of Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ijnp\/advance-article-pdf\/doi\/10.1093\/ijnp\/pyaf033\/63256069\/pyaf033.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ijnp\/article-pdf\/28\/6\/pyaf033\/63256069\/pyaf033.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ijnp\/article-pdf\/28\/6\/pyaf033\/63256069\/pyaf033.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T09:51:38Z","timestamp":1755597098000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ijnp\/article\/doi\/10.1093\/ijnp\/pyaf033\/8139655"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,21]]},"references-count":49,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6,6]]}},"URL":"https:\/\/doi.org\/10.1093\/ijnp\/pyaf033","relation":{},"ISSN":["1461-1457","1469-5111"],"issn-type":[{"value":"1461-1457","type":"print"},{"value":"1469-5111","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,6]]},"published":{"date-parts":[[2025,5,21]]},"article-number":"pyaf033"}}